Ascorbic acid as an adjunctive therapy in critically ill patients with COVID-19: a propensity score matched study

Abstract Ascorbic acid represents an appealing option for clinicians to utilize in the context of the global COVID-19 pandemic due to its proposed clinical efficacy, relative safety, and low cost. The aim of this study was to evaluate the efficacy and safety of using ascorbic acid in supplemental do...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Khalid Al Sulaiman, Ohoud Aljuhani, Khalid Bin Saleh, Hisham A. Badreldin, Abdullah Al Harthi, Mohammed Alenazi, Aisha Alharbi, Rahmah Algarni, Shmeylan Al Harbi, Abdullah M. Alhammad, Ramesh Vishwakarma, Sarah Aldekhyl
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/01acb48b22bb49dda4056fb524eebae5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:01acb48b22bb49dda4056fb524eebae5
record_format	dspace
spelling	oai:doaj.org-article:01acb48b22bb49dda4056fb524eebae52021-12-02T16:37:37ZAscorbic acid as an adjunctive therapy in critically ill patients with COVID-19: a propensity score matched study10.1038/s41598-021-96703-y2045-2322https://doaj.org/article/01acb48b22bb49dda4056fb524eebae52021-09-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-96703-yhttps://doaj.org/toc/2045-2322Abstract Ascorbic acid represents an appealing option for clinicians to utilize in the context of the global COVID-19 pandemic due to its proposed clinical efficacy, relative safety, and low cost. The aim of this study was to evaluate the efficacy and safety of using ascorbic acid in supplemental doses as adjunctive therapy for patients critically ill with COVID-19. This was a two-center, non-interventional, retrospective cohort study. All critically ill adult patients admitted to ICU with a confirmed COVID-19 diagnosis between March 1st and December 31st, 2020, were included in the final analysis. The study was conducted at two large governmental tertiary hospitals in Saudi Arabia. The purpose was to investigate the clinical outcomes of low-dose ascorbic acid as adjunctive therapy in COVID-19 after propensity score matching using baseline severity scores, systematic use of corticosteroids, and study centers. A number of 739 patients were included in this study, among whom 296 patients were included after propensity score matching. There was no association between the administration of ascorbic acid and in-hospital mortality or the 30-day mortality [OR (95% CI) 0.77 (0.47, 1.23), p value = 0.27 and OR (95% CI) 0.73 (0.43, 1.20), p value = 0.21, respectively]. Using ascorbic acid was associated with a lower incidence of thrombosis compared with the non-ascorbic-acid group [6.1% vs. 13% respectively; OR (95% CI) 0.42 (0.184, 0.937), p value = 0.03]. Low dose of ascorbic acid as an adjunctive therapy in COVID-19 critically ill patients was not associated with mortality benefits, but it was associated with a lower incidence of thrombosis. Further studies are required to confirm these findings.Khalid Al SulaimanOhoud AljuhaniKhalid Bin SalehHisham A. BadreldinAbdullah Al HarthiMohammed AlenaziAisha AlharbiRahmah AlgarniShmeylan Al HarbiAbdullah M. AlhammadRamesh VishwakarmaSarah AldekhylNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Khalid Al Sulaiman Ohoud Aljuhani Khalid Bin Saleh Hisham A. Badreldin Abdullah Al Harthi Mohammed Alenazi Aisha Alharbi Rahmah Algarni Shmeylan Al Harbi Abdullah M. Alhammad Ramesh Vishwakarma Sarah Aldekhyl Ascorbic acid as an adjunctive therapy in critically ill patients with COVID-19: a propensity score matched study
description	Abstract Ascorbic acid represents an appealing option for clinicians to utilize in the context of the global COVID-19 pandemic due to its proposed clinical efficacy, relative safety, and low cost. The aim of this study was to evaluate the efficacy and safety of using ascorbic acid in supplemental doses as adjunctive therapy for patients critically ill with COVID-19. This was a two-center, non-interventional, retrospective cohort study. All critically ill adult patients admitted to ICU with a confirmed COVID-19 diagnosis between March 1st and December 31st, 2020, were included in the final analysis. The study was conducted at two large governmental tertiary hospitals in Saudi Arabia. The purpose was to investigate the clinical outcomes of low-dose ascorbic acid as adjunctive therapy in COVID-19 after propensity score matching using baseline severity scores, systematic use of corticosteroids, and study centers. A number of 739 patients were included in this study, among whom 296 patients were included after propensity score matching. There was no association between the administration of ascorbic acid and in-hospital mortality or the 30-day mortality [OR (95% CI) 0.77 (0.47, 1.23), p value = 0.27 and OR (95% CI) 0.73 (0.43, 1.20), p value = 0.21, respectively]. Using ascorbic acid was associated with a lower incidence of thrombosis compared with the non-ascorbic-acid group [6.1% vs. 13% respectively; OR (95% CI) 0.42 (0.184, 0.937), p value = 0.03]. Low dose of ascorbic acid as an adjunctive therapy in COVID-19 critically ill patients was not associated with mortality benefits, but it was associated with a lower incidence of thrombosis. Further studies are required to confirm these findings.
format	article
author	Khalid Al Sulaiman Ohoud Aljuhani Khalid Bin Saleh Hisham A. Badreldin Abdullah Al Harthi Mohammed Alenazi Aisha Alharbi Rahmah Algarni Shmeylan Al Harbi Abdullah M. Alhammad Ramesh Vishwakarma Sarah Aldekhyl
author_facet	Khalid Al Sulaiman Ohoud Aljuhani Khalid Bin Saleh Hisham A. Badreldin Abdullah Al Harthi Mohammed Alenazi Aisha Alharbi Rahmah Algarni Shmeylan Al Harbi Abdullah M. Alhammad Ramesh Vishwakarma Sarah Aldekhyl
author_sort	Khalid Al Sulaiman
title	Ascorbic acid as an adjunctive therapy in critically ill patients with COVID-19: a propensity score matched study
title_short	Ascorbic acid as an adjunctive therapy in critically ill patients with COVID-19: a propensity score matched study
title_full	Ascorbic acid as an adjunctive therapy in critically ill patients with COVID-19: a propensity score matched study
title_fullStr	Ascorbic acid as an adjunctive therapy in critically ill patients with COVID-19: a propensity score matched study
title_full_unstemmed	Ascorbic acid as an adjunctive therapy in critically ill patients with COVID-19: a propensity score matched study
title_sort	ascorbic acid as an adjunctive therapy in critically ill patients with covid-19: a propensity score matched study
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/01acb48b22bb49dda4056fb524eebae5
work_keys_str_mv	AT khalidalsulaiman ascorbicacidasanadjunctivetherapyincriticallyillpatientswithcovid19apropensityscorematchedstudy AT ohoudaljuhani ascorbicacidasanadjunctivetherapyincriticallyillpatientswithcovid19apropensityscorematchedstudy AT khalidbinsaleh ascorbicacidasanadjunctivetherapyincriticallyillpatientswithcovid19apropensityscorematchedstudy AT hishamabadreldin ascorbicacidasanadjunctivetherapyincriticallyillpatientswithcovid19apropensityscorematchedstudy AT abdullahalharthi ascorbicacidasanadjunctivetherapyincriticallyillpatientswithcovid19apropensityscorematchedstudy AT mohammedalenazi ascorbicacidasanadjunctivetherapyincriticallyillpatientswithcovid19apropensityscorematchedstudy AT aishaalharbi ascorbicacidasanadjunctivetherapyincriticallyillpatientswithcovid19apropensityscorematchedstudy AT rahmahalgarni ascorbicacidasanadjunctivetherapyincriticallyillpatientswithcovid19apropensityscorematchedstudy AT shmeylanalharbi ascorbicacidasanadjunctivetherapyincriticallyillpatientswithcovid19apropensityscorematchedstudy AT abdullahmalhammad ascorbicacidasanadjunctivetherapyincriticallyillpatientswithcovid19apropensityscorematchedstudy AT rameshvishwakarma ascorbicacidasanadjunctivetherapyincriticallyillpatientswithcovid19apropensityscorematchedstudy AT sarahaldekhyl ascorbicacidasanadjunctivetherapyincriticallyillpatientswithcovid19apropensityscorematchedstudy
_version_	1718383612545466368

Ascorbic acid as an adjunctive therapy in critically ill patients with COVID-19: a propensity score matched study

Ejemplares similares